Semiquantitation of mouse dendritic cell migration in vivo using cellular MRI

Journal of Immunotherapy

Volumn 32, Issue 3, 2009, Pages 240-251

  Dekaban, Gregory A ^a   Snir, Jonatan ^a,b   Shrum, Bradly ^a   De Chickera, Sonali ^a,b   Willert, Christy ^a   Merrill, Mia ^a   Said, Elias A ^c   Sekaly, Rafick Pierre ^c   Foster, Paula J ^a,b   O'Connell, Peta J ^a,b,d  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d THERAPEUTIC GOODS ADMINISTRATION   (Australia)

Author keywords

Cancer; Dendritic cells; Immunotherapy; Magnetic resonance imaging; Vaccine

Indexed keywords

SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; CONTRAST MEDIUM; IRON; OXIDE; SUPERPARAMAGNETIC IRON OXIDE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL MATURATION; CELL MIGRATION; CELL STRUCTURE; CONTROLLED STUDY; DENDRITIC CELL; FLUORESCENCE MICROSCOPY; LYMPH NODE; MORPHOLOGICAL TRAIT; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; CELL MOTION; CHEMISTRY; CYTOLOGY; DRUG EFFECT; METHODOLOGY; PHYSIOLOGY;

ANIMALS; CELL MOVEMENT; CONTRAST MEDIA; DENDRITIC CELLS; IRON; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED C57BL; OXIDES;

EID: 67449096024     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318197b2a0     Document Type: Article

References (53)

1. Willimsky G, Blankenstein T. Sporadic immunogenic tumors avoid destruction by inducing T-cell tolerance. Nature. 2005; 437:141-146.
2. Muller A, Scherle PA. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat Rev. 2006;6:613-625.
3. Gilboa E. DC-based cancer vaccines. J Clin Invest. 2007;117: 1195-1203.
4. Dawson NA. New molecular targets in advanced prostate cancer. Expert Rev Anticancer Ther. 2006;6:993-1002.
5. Liu G, Black KL, Yu JS. Sensitization of maligant glioma to chemotherapy through dendritic cell vaccination. Expert Rev Vaccines. 2006;5:233-247.
6. O'Neill D, Bhardway N. Exploiting dendritic cells for active immunotherapy of cancer and chronic infections. Mol Biotechnol. 2007;36:131-141.
7. Collins MK, Cerundolo V. Gene therapy meets vaccine development. Trends Biotechnol. 2004;22:623-626.
8. Figdor CG, de Vries IJ, Lesterhuis WJ, et al. Dendritic cell immunotherapy: mapping the way. Nat Med. 2004;10:475-480.
9. + T cells and antiviral immunity. Immunity. 2004;20:47-58.
10. Ridgway D. The first 1000 dendritic cell vaccinees. Cancer Invest. 2003;21:873-886.
11. Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin Res. 2007;13:3776-3782.
12. Morel PA, Feili-Hariri M, Coates PT, et al. Dendritic cells, T cell tolerance and therapy of adverse immune reactions. Clin Exp Immunol. 2003;133:1-10.
13. Adema GJ, de Vries IJ, Punt CJ, et al. Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr Opin Immunol. 2005;17:170-174.
14. De Vries IJ, Krooshoop DJ, Scharenborg NM, et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 2003;63:12-17.
15. Eggert AA, Schreurs MW, Boerman OC, et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res. 1999;59: 3340-3345.
16. Eggert AA, van der Voort R, Torensma R, et al. Analysis of dendritic cell trafficking using EGFP-transgenic mice. Immunol Lett. 2003;89:17-24.
17. Josien R, Li HL, Ingulli E, et al. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J Exp Med. 2000; 191: 495-502.
18. Martin-Fontecha A, Sebastiani S, Hopken UE, et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med. 2003; 198:615-621.
19. Lindquist RL, Shakhar G, Dudziak D, et al. Visualizing dendritic cell networks in vivo. Nat Immunol. 2004;5: 1243-1250.
20. Heyn C, Ronald JA, Ramadan SS, et al. In vivo MRI of cancer cell fate at the single cell level in a mouse model of breast cancer metastasis to the brain. Magn Res Med. 2006;56: 1001-1010.
21. Baumjohann D, Hess A, Budinsky L, et al. In vivo magnetic resonance imaging of dendritic cell migration into the draining lymph nodes of mice. Eur J Immunol. 2006;36:2544-2555.
22. Prince HM, Wall DM, Ritchie D, et al. In Vivo tracking of dendritic cells in patients with multiple myeloma. J Immunother. 2008;31:166-179.
23. Johnson GA, Benveniste H, Black RD, et al. Histology by magnetic resonance microscopy. Magn Reson Q. 1993;9:1-30.
24. Heyn C, Bowen CV, Rutt BK, et al. Detection threshold of single SPIO-labeled cells with FIESTA. Magn Reson Med. 2005;53:312-320.
25. Benveniste H, Einstein G, Kim KR, et al. Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy. Proc Natl Acad Sci U S A. 1999;96:14079-14084.
26. Ahrens ET, Flores R, Xu H, et al. In vivo imaging platform for tracking immunotherapeutic cells. Nat Biotechnol. 2005;23: 983-987.
27. Bulte JW. Hot spot MRI emerges from the background. Nat Biotechnol. 2005;23:945-946.
28. Voisin P, Ribot ER, Miraux S, et al. Use of Lanthanide-grafted inorganic nanoparticles as effective contrast agents for cellular uptake imaging. BioConjug Chem. 2007;18:1053-1063.
29. Josephson L, Lewis J, Jacobs P, et al. The effects of iron oxides on proton relaxivity. Magn Reson Imaging. 1988;6:647-653.
30. + entry pathway. J Immunol. 2001;166:6126-6133.
31. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med. 1992;176:1693-1702.
32. Saville LR, Pospisil CH, Mawhinney LA, et al. A monoclonal antibody to CD11d reduces the inflammatory infiltrate into the injured spinal cord: a potential neuroprotective treatment. J Neuroimmunol. 2004;156:42-57.
33. Motlusky H. Intuitive Biostatistics. New York: Oxford University Press; 1995.
34. + T cells against tumors. Cancer Immunol Immunother. 2008;57:63-71.
35. Fadok VA, Savill JS, Haslett C, et al. Different populations of macrophages use either the vitronectin receptor or the phosphatidylserine receptor to recognize and remove apoptotic cells. J Immunol. 1992;149:4029-4035.
36. Sadhu C, Ting HJ, Lipsky B, et al. CD11c/CD18: novel ligands and a role in delated-type hypersensitivity. J Leukoc Biol. 2007;81:1395-1403.
37. Randolph GJ, Sanchez-Schmitz G, Angeli V. Factors and signals that govern the migartion of dendritic cells via lymphatics: recent advances. Semin Immun. 2005;26:273-287.
38. Roebuck KA, Finnegan A. Regulation of intercellular adhesion molecule-1 (CD54) gene expression. J Leuk Biol. 1999; 66:876-888.
39. Rosenberg S, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-915.
40. Ahrens ET, Feili-Hariri M, Xu H, et al. Receptor-mediated endocytosis of iron-oxide particles provides efficient labeling of dendritic cells for in vivo MR imaging. Magn Reson Med. 2003;49:1006-1013.
41. De Vries IJ, Lesterhuis W, Barentsz JO, Verdijk P, et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotech. 2005;23:1407-1413.
42. De Vries I, Lesterhuis W, Barentsz J, et al. MR tracking of magnetically-labeled dendritic cells to lymph nodes in melanoma patients: first clinical experience. Proc Int Soc Magn Reson Med. 2005;13:2603.
43. O'Neill DW, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood. 2004;104:2235-2246.
44. Vieweg J, Jackson A. Modulation of antitumor responses by dendritic cells. Springer Semin Immunopathol. 2005;26: 329-341.
45. Gupta AKNR, Vaidya VD, Gupta M. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Nanomedicine. 2007;2:23-39.
46. Sosnovik DEWR. Emerging concepts in molecular MRI. Curr Opin Biotechnol. 2007;18:4-10.
47. Strijkers GJMW, van Tilborg GA, Nicolay K. MRI contrast agents: current status and future perspectives. Anticancer Agents Med Chem. 2007;7:291-305.
48. Deshpande VS, Shea SM, Laub G, et al. 3D magnetization-prepared true-FISP: a new technique for imaging coronary arteries. Magn Reson Med. 2001;46:494-502.
49. Dunn EA, Weaver LC, Dekaban GA, et al. Cellular imaging of inflammation after experimental spinal cord injury. Mol Imaging. 2005;4:53-62.
50. Stuber MGW, Schar M, Kedziorek DA, et al. Positive contrast visualization of iron oxide-labeled stem cells using inversion-recovery with ON-resonant water suppression (IRON). Magn Reson Med. 2007;58:1072-1077.
51. Cunningham CHAT, Yang PC, McConnell MV, et al. Positive contrast magnetic resonance imaging of cells labeled with magnetic nanopartilces. Magn Reson Med. 2005;53:999-1005.
52. Mani VB-SK, Hyafil F, Itskovich V, et al. Positive magnetic resonance signal enhancement from ferritin using a GRASP (GRE acquisition for superparamagnetic particles) sequence: ex vivo and in vivo study. J Cardiovasc Magn Reson. 2006;8: 49-50.
53. Sappenwoolde JHVM, Bakker CJ. Passive tracking exploiting local signal conversion: the white marker phenomenon. Magn Reson Med. 2003;50:784-790.